About ThermiGen
ThermiGen is a company based in Austin (United States) founded in 2012 was acquired by Celling Biosciences in March 2019. ThermiGen has raised $8 million across 3 funding rounds from investors including SVB, Almirall and Celling Biosciences. ThermiGen operates in a competitive market with competitors including Primaeva Medical, INDIBA, EndyMed, Serene Medical and Invasix Aesthetic Solutions, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8 M (USD)
in 3 rounds
-
Latest Funding Round
$8 M (USD), Series A
Sep 01, 2015
-
Investors
SVB
& 3 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ThermiGen
Unlock access to complete
Unlock access to complete
Funding Insights of ThermiGen
ThermiGen has successfully raised a total of $8M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ThermiGen
ThermiGen has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Almirall and Celling Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Non-dilutive growth capital is provided by Cypress Growth Capital.
|
Locked | Locked | Locked | |
|
Generic finished formulations are manufactured and commercialized by Almirall.
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked |
Investor details for ThermiGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ThermiGen
Investment portfolio details for ThermiGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ThermiGen
Detailed financials for ThermiGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Thermigen Comparisons
Peer comparison for ThermiGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ThermiGen
ThermiGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Primaeva Medical, INDIBA, EndyMed, Serene Medical and Invasix Aesthetic Solutions, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Aesthetic treatment devices for dermatologists and cosmetic surgeons
|
|
| Locked | Locked | Locked |
Non-invasive devices for aesthetic treatments are developed by INDIBA.
|
|
| Locked | Locked | Locked |
Radiofrequency-based systems for aesthetic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Handheld device for selective modulation of target motor nerves to treat aesthetic conditions.
|
|
| Locked | Locked | Locked |
Aesthetic devices for body contouring, liposuction, skin rejuvenation, and cosmetic procedures.
|
Detailed competitors of ThermiGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thermigen
Complete news archive for ThermiGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ThermiGen
ThermiGen was founded in 2012 and raised its 1st funding round 1 year after it was founded.
ThermiGen is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Gianfranco Nazzi is the current CEO of ThermiGen.
ThermiGen is a funded company, having raised a total of $8M across 3 funding rounds to date.
ThermiGen was established in 2012 in Austin, United States, as a subsidiary of Almirall. Temperature-controlled radio frequency devices are produced for aesthetic and dermatology sectors, targeting skin tightening, excessive sweating reduction, feminine rejuvenation, and cellulite treatment. Key products include ThermiTight, ThermiVa, and ThermiSmooth, among others. FDA clearance has been obtained for the device lineup, supporting clinical applications in these fields.
ThermiGen's top competitors include INDIBA, Primaeva Medical and EndyMed.
ThermiGen has 4 investors. Key investors include SVB, Almirall, Celling Biosciences, and Cypress Growth Capital.